Biora Therapeutics, Inc. BIORQ
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -98.69% | -97.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -98.69% | -97.52% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -98.69% | -97.52% |
| SG&A Expenses | -- | -- | -- | -1.91% | -9.54% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -- | -- | -- | 8.15% | -1.88% |
| Operating Income | -- | -- | -- | -8.68% | 0.86% |
| Income Before Tax | -- | -- | -- | -152.64% | -2.49% |
| Income Tax Expenses | -- | -- | -- | 78.57% | 133.08% |
| Earnings from Continuing Operations | -- | -- | -- | -154.63% | -3.41% |
| Earnings from Discontinued Operations | -- | -- | -- | -97.95% | -130.15% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | -225.27% | -4.36% |
| EBIT | -- | -- | -- | -8.68% | 0.86% |
| EBITDA | -- | -- | -- | -9.37% | 0.09% |
| EPS Basic | -- | -- | -- | -72.74% | 44.56% |
| Normalized Basic EPS | -- | -- | -- | 16.43% | 66.99% |
| EPS Diluted | -- | -- | -- | -72.71% | 44.53% |
| Normalized Diluted EPS | -- | -- | -- | 16.43% | 66.99% |
| Average Basic Shares Outstanding | -- | -- | -- | 106.18% | 61.29% |
| Average Diluted Shares Outstanding | -- | -- | -- | 106.18% | 61.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |